In IBD, also the interplay between the IgG1-Fc domain of the anti-TNF antibodies and the Fcγ-receptors (FcγR) on macrophages accounts for the efficacy of the anti-TNF antibodies by increasing the number of regulatory CD206+ macrophages upon activation. The gene discussed is FCGR2A; the disease is inflammatory bowel disease.